1
|
Schneider BP, Karwal M, Laufman L, Sylvester L, Taylor MA, Sidor C, Hannah A, Arnott J, Miller KD. A phase II study of oral MKC-1 for metastatic breast cancer (MBC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Sylvester L, Laufman L, Jabboury K, Saleh M, Tkaczuk K, Volterra F, Arnott J, Hannah A, Sidor C, Miller K. Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity against a wide range of tumor cell lines, including multi-drug resistant cell lines. Proteins identified as binding targets of MKC-1 include microtubules (colchicine binding site) and members of the importin-β family (proteins that play a critical role in nuclear transport and spindle formation). Objective responses (ORs) were observed in heavily pre-treated breast and NSCLC pts (Trigo Perez ASCO’03 A62; Kurup ASCO’03 A2725) treated at a dose of 95 mg/m2 BID given 14 days every 4 weeks with little toxicity. Salazar et al (2004 CCR 10:4374) recommended a higher oral dose (125 mg/m2 BID) on this schedule for further studies. This phase 2 trial is exploring the higher dose to maximize potential anticancer activity. Methods: Pts with MBC who had failed prior A and T and met eligibility criteria received MKC-1 at 125mg/m2 BID x 14d every 4 weeks. Pts with known treated and stable CNS metastases could enroll. Primary objective: OR by RECIST. Should 2 or more of the first 23 evaluable pts have an OR, enrollment will continue to 53 pts. Dose escalation/reductions are required based on toxicity (primarily neutropenia). Results: To date, a total of 20 pts have been enrolled (4 active in Cycles 1–5+). All female; median age/KPS of 60/90. 19% / 13% had received A / T in the neo/adjuvant setting; others had received A / T for metastatic disease. To date, a total of 48 cycles (median 2, range 1–8) were administered; of pts proceeding into Cycle 2, 40% and 20% had the dose increased or reduced, respectively. Severe drug-related toxicity (n=17) was observed in 3 pts (18%): ↑AST/ALT in 2 pts and parathesias in 1 pt. Drug related toxicity: nausea (47%), ↑ALT, diarrhea (both 24%), anemia, ↑AST, cough, fatigue, neutropenia and vomiting (all 18%). Two pts discontinued due to toxicity. One pt had complete resolution of measurable disease (1st observed after Cycle 4, confirmed after Cycle 6 with withdrawal for a new lesion at Cycle 8). An additional 2 pts had stable disease for 5 cycles (1 pt remains active). Conclusions: MKC-1 is well tolerated at the initial recommended dose for this schedule. Activity is observed in pts previously treated with A/T for MBC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Sylvester
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - L. Laufman
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Jabboury
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - M. Saleh
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Tkaczuk
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - F. Volterra
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - J. Arnott
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - A. Hannah
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - C. Sidor
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Miller
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| |
Collapse
|
3
|
Visnegarwala F, Rodriguez-Barradass MC, Graviss EA, Caprio M, Nykyforchyn M, Laufman L. Community outreach with weekly delivery of anti-retroviral drugs compared to cognitive-behavioural health care team-based approach to improve adherence among indigent women newly starting HAART. AIDS Care 2007; 18:332-8. [PMID: 16809110 DOI: 10.1080/09540120500162155] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Sustained virological suppression requires adherence to >95% of doses of therapy. Overall there is paucity of data on adherence interventions among women and post-intervention outcomes. In this pilot study, we evaluated a novel strategy of weekly delivery of medications (Directly Delivered Therapy: DDT) for six months using an outreach worker (ORW), among ARV naïve indigent women starting HAART and compared the 'during intervention' and 'post-intervention' outcomes to the health care team (a nurse educator, a case worker, a pharmacist and social worker/drug addictions counsellor) based approach termed Adherence Coordination Services (ACS) and the Standard of Care (SoC) historical referent group. The baseline characteristics of the three groups were comparable. The proportion of women who achieved sustained virologic suppression in 4-8 month period for DDT; ACS and SoC groups were 86% (18/21); 54% (6/11); and 36% (8/22) (P<0.004); and in the 10-14 month period were 80% (12/15); 54% (6/11) and 45%(10/22) (P=0.036 for DDT vs. SoC). Retention rate in the DDT was 87%, and 92% of 307 ORW visits were kept, and post-intervention satisfaction was high. Short-term weekly delivery of medications using a community based liaison is a feasible, acceptable and a cost-effective strategy for improving both short-term and perhaps long-term adherence among women initiating their first HAART regimen.
Collapse
Affiliation(s)
- F Visnegarwala
- Department of Medicine, Section of Infectious Diseases, Baylor College Of Medicine, One Baylor Plaza, Room #465 EC, Houston, TX 77030, USA.
| | | | | | | | | | | |
Collapse
|
4
|
Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. J Clin Oncol 2005; 23:5542-51. [PMID: 16110015 DOI: 10.1200/jco.2005.02.027] [Citation(s) in RCA: 390] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PurposeThis randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen.Patients and MethodsPatients (n = 449) were randomly assigned to receive either docetaxel 100 mg/m2(n = 225) or paclitaxel 175 mg/m2(n = 224) on day 1, every 21 days until tumor progression, unacceptable toxicity, or withdrawal of consent.ResultsIn the intent-to-treat population, both the median overall survival (OS, 15.4 v 12.7 months; hazard ratio [HR], 1.41; 95% CI, 1.15 to 1.73; P = .03) and the median time to progression (TTP, 5.7 months v 3.6 months; HR, 1.64; 95% CI, 1.33 to 2.02; P < .0001) for docetaxel were significantly longer than for paclitaxel, and the overall response rate (ORR, 32% v 25%; P = .10) was higher for docetaxel. These results were confirmed by multivariate analyses. The incidence of treatment-related hematologic and nonhematologic toxicities was greater for docetaxel than for paclitaxel; however, quality-of-life scores were not statistically different between treatment groups over time.ConclusionDocetaxel was superior to paclitaxel in terms of OS and TTP. ORR was higher for docetaxel. Hematologic and nonhematologic toxicities occurred more frequently in the docetaxel group. The global quality-of-life scores were similar for both agents over time.
Collapse
Affiliation(s)
- S E Jones
- Texas Oncology, 3535 Worth St, Suite 600, Dallas, TX 75246, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Spiridonidis H, Tao M, Laufman L, Laufman H, Weiss M, Ganz P. Symptomatic response to a non-platinum doublet in performance status 2 (PS 2) patients (pts) with non-small lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Spiridonidis
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| | - M. Tao
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| | - L. Laufman
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| | - H. Laufman
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| | - M. Weiss
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| | - P. Ganz
- Hematology Oncology Consultants Inc, Columbus, OH; UCLA, Los Angeles, CA
| |
Collapse
|
6
|
Justice E, Sharma J, Justice J, Kripalani S, Spiker C, Jacobson TA, Laufman L, Weinberg AD. 265 A RANDOMIZED CONTROLLED TRIAL TO PROMOTE PHYSICIAN-PATIENT DISCUSSION OF PROSTATE CANCER SCREENING. J Investig Med 2004. [DOI: 10.1136/jim-52-suppl1-818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Justice E, Sharma J, Justice J, Kripalani S, Spiker C, Jacobson TA, Laufman L, Weinberg AD. A RANDOMIZED CONTROLLED TRIAL TO PROMOTE PHYSICIAN-PATIENT DISCUSSION OF PROSTATE CANCER SCREENING. J Investig Med 2004. [DOI: 10.1097/00042871-200401001-00818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Ravdin P, Erban J, Overmoyer B, Budd G, Hutchins L, Lower E, Laufman L, Sundaram S, Urba W, Olsen S, Meyers M, Jones S. 670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC). EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90701-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Abstract
BACKGROUND Pediatric residents have the need for additional training in the care of common musculoskeletal injuries. OBJECTIVES To implement and evaluate the effects of a teaching intervention on pediatric residents' knowledge and skills in performing the physical examination of the ankle and knee. STUDY DESIGN Prospective, intervention, single-sample study design. METHODS Pediatric residents (n = 58) on a 1-month adolescent medicine rotation received a teaching intervention after a baseline evaluation of their knowledge and skills. The teaching intervention was designed to improve their knowledge about and skills in performing physical examinations of the ankle and knee. The intervention included watching a videotape, followed by observation of the attending physician demonstrating the techniques on a standardized patient, followed by correct demonstration of the techniques by the resident. The residents' knowledge and skills were assessed at the end of the rotation and 9 months later. Knowledge was assessed using a written examination. Skills assessment was performed using a Clinical Skills Assessment Examination. RESULTS At baseline, the residents performed 37% of the ankle and 18% of the knee physical examination techniques correctly. At 1 and 9 months, the residents' knowledge of ankle and knee examinations was greater than at baseline. The residents performed 77% of the techniques correctly at 1 month and 67% at 9 months. The residents performed 55% of the knee examination techniques correctly at 1 month and 47% at 9 months. The teaching intervention was rated highly by the residents. CONCLUSIONS The residents' performance of ankle and knee examinations was suboptimal at baseline and improved significantly after the teaching intervention. Observed improvements persisted for a mean of 35 weeks. The teaching intervention described in this study could meet the need for improved ankle and knee examination skills, the 2 most common sites of skeletal injury in young athletes. The teaching model is novel in that it couples videotape and skills-based teaching methods with reliable evaluation methods. This model teaching method could be adapted for use in other pediatric residency training programs and other content areas. musculoskeletal, physical examination, resident curriculum.
Collapse
Affiliation(s)
- A C Hergenroeder
- Department of Pediatrics, Adolescent Medicine and Sports Medicine Section, Baylor College of Medicine, Houston, Texas 77030-2399, USA.
| | | | | | | |
Collapse
|
10
|
Hergenroeder AC, Laufman L, Chorley JN, Fetterhoff AC. Development and evaluation of a method for evaluating pediatric residents' knowledge and skill in performing physical examinations of the ankle and knee. Pediatrics 2001; 107:E51. [PMID: 11335772 DOI: 10.1542/peds.107.4.e51] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Pediatric residents need the knowledge and physical examination skills to evaluate common musculoskeletal injuries. The ankle and the knee are the 2 most common sites of musculoskeletal injury in young athletes. Methods for evaluating pediatric residents' knowledge and skills in examining the ankle and knee are needed. OBJECTIVES 1) To describe the development of a method for evaluating pediatric residents' knowledge and skill in performing physical examinations of the ankle and knee, and 2) to report the reliability of this method. METHODS A written test and a Clinical Skills Assessment Examination (CSAE) with a rating index were developed by the investigators to evaluate pediatric residents' knowledge and skills in examining the ankle and knee. Fifty-eight pediatric residents completed the written test and examined the ankle and knee of one standardized patient at the beginning of a required 1-month adolescent medicine rotation. Forty-eight residents repeated the evaluation at the end of the month. The investigators rated the residents' performance of the CSAE and then assessed interrater reliability using Cronbach's alpha. Test-retest correlation was calculated to assess the reliability of the written test. RESULTS Test-retest correlation for the written test was 0.72, establishing its reliability. Interrater reliability for rating the CSAE of the ankle and knee was 0.98 and 0.90, respectively. CONCLUSION Pediatric residents' knowledge and skills in examining the ankle and knee can be reliably evaluated using the written test and CSAE described in this article. These could be used to assess the effectiveness of current curricula in improving pediatric residents' knowledge and skill in evaluating ankle and knee complaints and to assist in the design of future curricula. musculoskeletal, evaluation methods, resident curriculum.
Collapse
Affiliation(s)
- A C Hergenroeder
- Department of Pediatrics, Adolescent Medicine and Sports Medicine Section, Baylor College of Medicine, Houston, Texas 77030-2399, USA.
| | | | | | | |
Collapse
|
11
|
Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19:1750-8. [PMID: 11251006 DOI: 10.1200/jco.2001.19.6.1750] [Citation(s) in RCA: 159] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To study the additional benefit from adenoviral p53 gene therapy in patients undergoing first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Twenty-five patients with nonresectable NSCLC were enrolled in an open-label, multicenter phase II study of three cycles of regimen A, carboplatin (area under the curve, 6; day 1) plus paclitaxel (175 mg/m(2), day 1), or regimen B, cisplatin (100 mg/m(2), day 1) plus vinorelbine (25 mg/m(2), days 1, 8, 15, and 22) in combination with intratumoral injection of 7.5 x 10(12) particles of SCH 58500 (rAd/p53, day 1). Responses of individual tumor lesions were assessed after each cycle, and gene transfer was examined in posttreatment tumor biopsies using reverse transcriptase polymerase chain reaction. RESULTS There was no difference between the response rate of lesions treated with p53 gene therapy in addition to chemotherapy (52% objective responses) and lesions treated with chemotherapy alone (48% objective responses). Subgroup analysis according to the chemotherapy regimens revealed evidence for increased mean local tumor regressions in response to additional p53 gene therapy in patients receiving regimen B, but not in patients receiving regimen A. There was no survival difference between the two chemotherapy regimens, and the median survival of the cohort was 10.5 months (1-year survival, 44%). Transgene expression was confirmed in tumor samples from 68% of patients, and toxicities attributable to gene therapy were mild to moderate. CONCLUSION Intratumoral adenoviral p53 gene therapy appears to provide no additional benefit in patients receiving an effective first-line chemotherapy for advanced NSCLC.
Collapse
Affiliation(s)
- M Schuler
- Department of Medicine III, Johannes Gutenberg University, Mainz, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
PURPOSE This study examined breast and cervical cancer knowledge, attitudes, and screening behaviors among different Hispanic populations in the United States. DESIGN Data were collected from a random digit dial telephone survey of 8903 Hispanic adults from eight U.S. sites. Across sites, the average response rate was 83%. SETTING Data were collected as part of the baseline assessment in a national Hispanic cancer control and prevention intervention study. SUBJECTS Analysis was restricted to 2239 Hispanic women age 40 and older who were self-identified as either Central American (n = 174), Cuban (n = 279), Mexican American (n = 1550), or Puerto Rican (n = 236). MEASURES A bilingual survey instrument was used to solicit information on age, education, income, health insurance coverage, language use, U.S.-born status, knowledge of screening guidelines, attitudes toward cancer, and screening participation. Differences in knowledge and attitudes across Hispanic groups were assessed by either chi-square tests or analysis of variance. Logistic regression models assessed the influence of knowledge and attitudes on screening participation. RESULTS The level of knowledge of guidelines ranged from 58.3% (Mexican Americans) to 71.8% (Cubans) for mammography, and from 41.1% (Puerto Ricans) to 55.6% (Cubans) for Pap smear among the different Hispanic populations. Attitudes also varied, with Mexican Americans and Puerto Ricans having more negative or fatalistic views of cancer than Cuban or Central Americans. Knowledge was significantly related to age, education, income, language preference, and recent screening history. Overall, attitudes were not predictive of mammography and Pap smear behavior. CONCLUSIONS Factors related to mammography and Pap smear screening vary among the different Hispanic populations. Limitations include the cross-sectional nature of the study, self-reported measures of screening, and the limited assessment of attitudes. The data and diversity of Hispanic groups reinforce the position that ethno-regional characteristics should be clarified and addressed in cancer screening promotion efforts. The practical relationships among knowledge, attitudes, and cancer screening are not altogether clear and require further research.
Collapse
Affiliation(s)
- A G Ramirez
- Baylor College of Medicine, San Antonio, Texas, USA
| | | | | | | | | |
Collapse
|
13
|
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17:3374-88. [PMID: 10550131 DOI: 10.1200/jco.1999.17.11.3374] [Citation(s) in RCA: 181] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE In 1989, the National Surgical Adjuvant Breast and Bowel Project initiated the B-22 trial to determine whether intensifying or intensifying and increasing the total dose of cyclophosphamide in a doxorubicin-cyclophosphamide combination would benefit women with primary breast cancer and positive axillary nodes. B-25 was initiated to determine whether further intensifying and increasing the cyclophosphamide dose would yield more favorable results. PATIENTS AND METHODS Patients (n = 2,548) were randomly assigned to three groups. The dose and intensity of doxorubicin were similar in all groups. Group 1 received four courses, ie, double the dose and intensity of cyclophosphamide given in the B-22 standard therapy group; group 2 received the same dose of cyclophosphamide as in group 1, administered in two courses (intensified); group 3 received double the dose of cyclophosphamide (intensified and increased) given in group 1. All patients received recombinant human granulocyte colony-stimulating factor. Life-table estimates were used to determine disease-free survival (DFS) and overall survival. RESULTS No significant difference was observed in DFS (P =.20), distant DFS (P =.31), or survival (P =.76) among the three groups. At 5 years, the DFS in groups 1 and 2 (61% v 64%, respectively; P =. 29) was similar to but slightly lower than that in group 3 (61% v 66%, respectively; P = 08). Survival in group 1 was concordant with that in groups 2 (78% v 77%, respectively; P =.71) and 3 (78% v 79%, respectively; P =.86). Grade 4 toxicity was 20%, 34%, and 49% in groups 1, 2, and 3, respectively. Severe infection and septic episodes increased in group 3. The decrease in the amount and intensity of cyclophosphamide and delays in therapy were greatest in courses 3 and 4 in group 3. The incidence of acute myeloid leukemia increased in all groups. CONCLUSION Because intensifying and increasing cyclophosphamide two or four times that given in standard clinical practice did not substantively improve outcome, such therapy should be reserved for the clinical trial setting.
Collapse
Affiliation(s)
- B Fisher
- National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212-5234, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567-74. [PMID: 7595708 DOI: 10.1200/jco.1995.13.10.2567] [Citation(s) in RCA: 119] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE This prospective multicenter randomized trial was performed to compare the effectiveness and safety of intravenous (i.v.) vinorelbine tartrate (Navelbine [NVB]; Burroughs Wellcome Co, Research Triangle Park, NC) with i.v. melphalan (Alkeran [ALK]; Burroughs Wellcome Co) in a heavily pretreated population of patients with anthracycline-refractory advanced breast cancer (ABC). Efficacy end points included time to disease progression (TDP), time to treatment failure (TTF), survival, tumor response rates, and quality of life (QL) and relief of cancer-related symptoms. PATIENTS AND METHODS Between August 24, 1990, and December 1, 1992, 183 patients were randomized (2:1) to treatment with NVB (30 mg/m2 weekly) or ALK (25 mg/m2 every 4 weeks) i.v. Patients were stratified by measurable or nonmeasurable-assessable disease and by treatment center. RESULTS Time to disease progression was significantly longer with NVB than with ALK, with a median 12 weeks versus 8 weeks, respectively (P < .001). NVB patients also had significantly longer time to treatment failure than ALK patients, with a median 12 weeks versus 8 weeks, respectively (P < .001). The effect of NVB on survival was also statistically significant (P = .034): 1-year survival rates were 35.7% with NVB and 21.7% with ALK and the median survival rate was 35 weeks and 31 weeks, respectively. In total, 46.5% of NVB patients and 28.2% of ALK patients achieved an objective response or stabilization of disease (P = .06). No intergroup differences were noted in patient-assessed QL and cancer-related symptoms. The most common toxicities were hematologic, including granulocytopenia with NVB and thrombocytopenia and granulocytopenia with ALK. Both drugs were generally well tolerated, and no septic deaths were reported. CONCLUSION This randomized trial demonstrates a survival benefit in anthracycline-refractory ABC. NVB was well tolerated and demonstrated activity superior to ALK in anthracycline-refractory ABC, without compromising QL. Based on activity of single-agent NVB in this difficult-to-treat patient population, investigations of NVB in combination with other anticancer drugs are warranted.
Collapse
Affiliation(s)
- S Jones
- Baylor University Medical Center, Dallas, TX, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Cain JM, Liu PY, Alberts DE, Gallion HH, Laufman L, O'Sullivan J, Weiss G, Bickers JN. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. Invest New Drugs 1992; 10:23-4. [PMID: 1607250 DOI: 10.1007/bf01275473] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
Collapse
Affiliation(s)
- J M Cain
- Puget Sound Oncology Consortium, Seattle, WA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Oishi N, Fleming TR, Laufman L, Ungerleider JS, Natale RB, Einstein AB, Von Hoff DD, Macdonald JS. VM-26 in colorectal carcinoma: a Southwest Oncology Group study. Invest New Drugs 1990; 8:93-5. [PMID: 2188930 DOI: 10.1007/bf00216931] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.
Collapse
Affiliation(s)
- N Oishi
- Cancer Research Center of Hawaii
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Twenty-seven patients with cutaneous and subcutaneous malignant neoplasms were treated with photodynamic therapy. Therapy was administered to 248 areas during a total of 72 separate treatment sessions after patients received a total of 45 injections of sensitizer. Seven patients had basal cell carcinoma, three had squamous cell carcinoma, three had malignant melanoma, one had liposarcoma, and 12 had breast cancers. One patient had Bowen's disease. Treatment was given either by surface radiation or interstitially. One month after treatment, 48 (67%) of the treatment sessions resulted in a complete response (no clinical evidence of tumor), and 19 (26%) resulted in a partial response (greater than 50% reduction in the number or size of tumors). Fifteen patients were examinable 12 months after treatment, and in this group, 31 treatment sessions were evaluated as a complete response one month after therapy, 15 (48%) of which retained this status at one year after treatment. By comparing the ability of different light-delivery instrumentation, it was concluded that the Yellow Springs radiometer (Yellow Springs Instruments, model 65A, Yellow Springs, Ohio) provided the most reliable spot power density readings. Straight-tipped fibers are nonhomogeneous and can result in overtreatment of the central area with necrosis and pain and in undertreatment of the periphery.
Collapse
|
18
|
Sirota H, Rubovits DR, Cousins JH, Weinberg AD, Laufman L, Lane M. Cancer control: communication. Health Values 1988; 12:30-2. [PMID: 10290034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/13/2023]
|
19
|
Sirota H, Rubovits DR, Cousins JH, Weinberg AD, Laufman L, Lane M. Cancer control: early detection and treatment. Health Values 1988; 12:37-41. [PMID: 10290036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
20
|
Sirota H, Rubovits DR, Cousins JH, Weinberg AD, Laufman L, Lane M. Cancer control: prevention. Health Values 1988; 12:33-6. [PMID: 10290035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
21
|
Sirota H, Rubovits DR, Cousins JH, Weinberg AD, Laufman L, Lane M. Cancer control: special populations. Health Values 1988; 12:46-50. [PMID: 10290037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
22
|
Panettiere FJ, Goodman PJ, Costanzi JJ, Cruz AB, Vaitkevicius VK, McCracken JD, Brownlee RW, Laufman L, Stephens RL, Bonnet J. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol 1988; 6:947-54. [PMID: 3286830 DOI: 10.1200/jco.1988.6.6.947] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The Southwest Oncology Group (SWOG) colorectal adjuvant study 7510 went through two phases. From 1975 to 1977, 309 patients were randomized to chemotherapy alone or the same chemotherapy plus immunotherapy. From 1977 until 1980, 317 patients were randomized among the same two therapy programs and a control group. With a minimum follow-up in either phase of greater than 7 years, data are now mature. They show no difference in relapse-free survival (RFS) nor overall survival (OS) in either the two-way phase or in the three-way phase. There is no indication, except possibly in one very small subset, that the addition of immunotherapy to chemotherapy provides an improvement in OS or in RFS. Using data from patients accrued after randomization to the control group, we fail to find evidence that either chemotherapy alone or chemoimmunotherapy improves OS or RFS when contrasted to outcomes obtained by patients on the control arm. In fact, we have significant evidence, at the P = .016 level, that chemotherapy does not improve OS by at least 50%; we also have significant evidence, at the P = .011 level, that chemoimmunotherapy will not improve OS by at least 25%. No evidence of efficacy was demonstrated for either treatment regimen, even though enough therapy was given to result in significant toxicities. Acute toxicity was at least moderate, but not fatal, in 75% of patients. Recognizable delayed toxicity included rare cases of fatal renal failure and acute leukemia.
Collapse
Affiliation(s)
- F J Panettiere
- University of Arkansas for Medical Sciences, Little Rock
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Iammarino NK, Laufman L, Scott LW, Weinberg AD. Development and evaluation of the help-your-heart diet game. Hygie 1987; 6:15-20. [PMID: 3583279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
24
|
Abstract
Seven patients with severe or complete obstruction of the esophagus by malignancy were treated with photoradiation after presensitization of the tumor with intravenous hematoporphyrin derivative. The 625- to 635-nm therapeutic light was delivered from a tunable dye argon laser system coupled through quartz fibers, passed through the biopsy channel of a flexible esophagoscope, with local anesthesia. All tumors (adeno, squamous, and melanoma) responded, and swallowing was improved. Although tumor is still present, one patient is 11 months from initial treatment and is eating a regular diet. Another patient is 8 months from initial treatment and has no dysphagia. One patient died of aspiration of gastric tube feedings and 3 others died of their disease at 3 weeks, 3 months, and 6 months, respectively, from their initial treatment. Another patient died 11 months from his initial treatment due to a cardiac arrhythmia. During the 11 months after his initial treatment he continued to eat a regular diet.
Collapse
|
25
|
Abstract
The purpose of this study was to identify what high school students do not know about the cardiovascular system, its diseases and their prevention. A total of 135 questions were administered to 3,000 students around the country. Student responses were analyzed by general knowledge area, taxonomic levels of knowledge required to answer and response patterns within individual test items. The results are discussed in terms of guidelines for health education.
Collapse
|
26
|
McCaughan JS, Guy JT, Hawley P, Hicks W, Inglis W, Laufman L, May E, Nims TA, Sherman R. Hematoporphyrin-derivative and photoradiation therapy of malignant tumors. Lasers Surg Med 1983; 3:199-209. [PMID: 6668975 DOI: 10.1002/lsm.1900030302] [Citation(s) in RCA: 36] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Kodak projectors with #2418 red Corning filters were used as a light source to treat cutaneous and subcutaneous malignancies in five patients who previously had been given hematoporphyrin derivative (HpD). An argon dye laser system was used to treat malignancies in patients who also were given the HpD. These tumors included 11 melanomas of the eye, three carcinomas of the esophagus, one melanoma of the esophagus, four carcinomas of the lung, three basal cell skin cancers, and one retropharyngeal metastatic oral cancer. Clinical results and technical problems of this therapy are discussed.
Collapse
|
27
|
Laufman L, Iammarino NK, Weinberg AD. The nominal group technique: a health education strategy. Health Educ 1981; 12:17-9. [PMID: 6792111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
28
|
Holcomb JD, Laufman L, Roush RE, Spiker CA, Weinberg AD, Iammarino NK. The use of self-instructional units on cardiovascular disease prevention in a university setting. J Am Coll Health Assoc 1980; 28:346-50. [PMID: 7391421 DOI: 10.1080/01644300.1980.10392943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
29
|
Laufman L, Weinstein J. Values and prevention. Health Values 1978; 2:270-3. [PMID: 10239127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|